Solasia Pharma K.K. announced consolidated earnings results for the first quarter ended March 31, 2020. For the quarter, the company reported revenue of JPY 156 million against JPY 61 million a year ago. Operating loss was JPY 534 million against JPY 494 million a year ago. Loss attributable to owners of parent was JPY 531 million against JPY 560 million a year ago. Basic loss per share was JPY 4.57 against JPY 5.35 a year ago.

For the fiscal year ending December 31, 2020, for the period, the company expects revenue to be between JPY 500 million and JPY 2,000 million, operating loss to be between JPY 2,900 million and JPY 2,000 million, Loss attributable to owners of parent to be between JPY 2,900 million and JPY 2,000 million a year ago. Basic loss per share expects to be between JPY 24.91 and JPY 17.18.